Abstract: The present invention includes a method of using PHY906 for treating a bowel disorder including inflammatory bowel disease and irritable bowel syndrome. Particularly, the present invention provides a multiple symptoms treatment for the bowel disorder.
Type:
Grant
Filed:
October 29, 2020
Date of Patent:
September 27, 2022
Assignee:
YALE UNIVERSITY
Inventors:
Yung-Chi Cheng, Shwu-Huey Liu, Robert Tilton
Abstract: Techniques for implementing robust quantum logic gates are provided and described. In some aspects, a quantum logic gate between a plurality of cavities comprising a first cavity and a second cavity is implemented by performing a first beam splitter operation between the first cavity and the second cavity using a coupling transmon that is dispersively coupled to both the first cavity and the second cavity, and performing a controlled phase shift operation between the second cavity and an ancilla transmon that is dispersively coupled to the second cavity but not dispersively coupled to the first cavity.
Type:
Grant
Filed:
January 5, 2019
Date of Patent:
September 20, 2022
Assignee:
Yale University
Inventors:
Liang Jiang, Steven M. Girvin, Brian Lester, Yvonne Gao, Robert J. Schoelkopf, III
Abstract: Techniques for providing hardware-efficient fault-tolerant quantum operations are provided. In some aspects a cavity and an ancilla transmon are used to implement a quantum operation by encoding a logical qubit using more than two energy levels of the cavity, encoding information using more than two energy levels of the ancilla transmon, and creating an interaction between the cavity and the ancilla transmon that decouples at least one error type in the ancilla transmon from the cavity.
Type:
Grant
Filed:
January 5, 2019
Date of Patent:
September 20, 2022
Assignee:
Yale University
Inventors:
Serge Rosenblum, Philip Reinhold, Liang Jiang, Steven M. Girvin, Luigi Frunzio, Michel Devoret, Robert J. Schoelkopf, III
Abstract: The present invention includes a low dose and sustained release formulation of a mitochondrial uncoupling agent The compositions of the invention are useful for preventing or treating a disease or disorder, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin resistance and/or diabetes, in a subject in need thereof.
Type:
Grant
Filed:
July 22, 2020
Date of Patent:
September 6, 2022
Assignee:
YALE UNIVERSITY
Inventors:
Gerald I. Shulman, Rachel Jamison Perry
Abstract: Systems and methods for formal verification of programs. The systems and methods provide a new game-theoretical, strategy-based compositional semantic model for concurrency, a set of formal linking theorems for composing multithreaded and multicore concurrent layers, and a compiler that supports certified thread-safe compilation and linking. Verification of an overlay interface can include determining an intermediate strategy for a primitive operation running on an underlay interface and refining that intermediate strategy to a strategy running on the overlay interface by applying a vertical and a horizontal composition rule. The refined strategy can then be composed with compatible strategies running on the overlay interface according to a parallel composition rule. Strategies may be compatible when rely conditions imposed by each strategy satisfy guarantees provided by the other strategies. The system and method of formal verification can be applied to formal verification of smart contracts.
Type:
Grant
Filed:
November 28, 2018
Date of Patent:
August 9, 2022
Assignee:
Yale University
Inventors:
Zhong Shao, Ronghui Gu, Vilhelm Sjoberg, Jieung Kim, Jeremie Koenig
Abstract: The present invention relates in part to devices, systems, and methods for the production and characterization of engineered tissue constructs. The devices and methods generate decellularized tissue constructs that can be recellularized using donor cells for high-throughput studies of organ physiology, and/or organ pathology. The devices and methods can be used with the systems to mechanically and electrically stimulate the engineered tissue constructs under culture or physiological conditions to detect and assess the presence and degree of any organ pathologies.
Type:
Grant
Filed:
January 30, 2018
Date of Patent:
August 9, 2022
Assignee:
Yale University
Inventors:
Stuart Campbell, Jonas Schwan, Andrea Kwaczala, Thomas Ryan, Daniel Jacoby, Yibing Qyang, Lorenzo Sewanan, Ronald Ng, Jeffery Alexander Clark
Abstract: Methods and strategies for introducing genetic safeguards into microorganisms, genetically modified organisms (GMO) including the safeguards, and methods of use thereof are provided. The genetic safeguards generally impart a low escape frequency, are robust, and are modular. Safeguards with low escape frequency prevent the rise of mutants escaping defined media and limit growth in the wild. Robust safeguards retain wild-type levels of fitness while also maintaining containment in diverse growth conditions.
Type:
Grant
Filed:
September 28, 2015
Date of Patent:
August 9, 2022
Assignee:
YALE UNIVERSITY
Inventors:
Farren J. Isaacs, Ryan Gallagher, Jaymin Patel, Alexis Rovner
Abstract: Described herein are the association BV677278 (READ1) with reading disability and language impairment, as well as the synergistic interaction of DCDC2 risk haplotypes or alleles with KIAA0319 risk allele.
Abstract: Disclosed herein are methods and agents for the treatment of cancer using p53-independent apoptosis to reduce the number of p53-depleted or p53-mutated cancer cells that have amplified HER2 gene. Also disclosed herein are methods and agents for the treatment of HER2-positive cancer in individuals with Li-Fraumeni Syndrome.
Abstract: The present application provides agents that specifically inhibits the IGFBP7/CD93 signaling pathway, such as agents that specifically block the interaction between CD93 and IGFBF7, methods of using said agents and methods of identifying said agents.
Type:
Application
Filed:
March 25, 2022
Publication date:
July 28, 2022
Applicants:
YALE UNIVERSITY, The Regents of the University of Colorado, a body corporate
Inventors:
Yuwen ZHU, Lieping CHEN, Richard SCHULICK, Yi SUN
Abstract: The invention provides methods for selective targeting of live cells, which have undergone or are undergoing radiation or chemotherapy, at a site of interest with a cell-penetrating polypeptide. In one embodiment of the invention, the method comprises contacting the live cells with a cell-penetrating polypeptide comprising cell-penetrating determinants so that the cell-penetrating polypeptide binds extracellular DNA near or around the live cells so as to form a complex or association therewith such that the complex or associated polypeptide-DNA so bound bind the live cells and penetrates the live cells thereby selectively targeting live cells at a site of interest with a cell-penetrating polypeptide.
Abstract: The present invention provides compositions and methods of preparing airway cells. In one aspect, an epithelial airway cell derived from an induced pluripotent stem (iPS) cell characterized by expression of airway cell surface markers and an ability to proliferate is described. In another aspect, methods of differentiating an iPS into an epithelial airway cell is provided. Engineered lungs, methods of making such engineered lungs comprising the epithelial airway cells and treating respiratory disorders are also disclosed.
Abstract: The present invention includes compositions and methods for treating stroke in sickle cell anemia (SCA) patients. In certain embodiments, the patient is administered certain ENPP1- or ENNP3-containing polypeptides, mutants, or mutant fragments thereof.
Abstract: The invention provides compositions and methods for identifying DNA methylation. In one embodiment, the invention provides a method for detecting N6-methyladenine.
Abstract: Devices and systems for opto-acoustic signal processing are described herein. In one embodiment, the device may include a structure configured to laterally confine travelling acoustic phonons (hypersound) throughout, a first multimode optical waveguide embedded within the structure, and an acoustic phonon emitter within the structure, where the first multimode optical waveguide is selected to couple to the acoustic phonons (hypersound) confined within the structure. In one embodiment, the system may include a first light source optically coupled to a proximal end of the first multimode optical waveguide, the first light source emitting a probe wave having a frequency ?p(1), and a driver configured to drive the acoustic phonon emitter to emit acoustic phonons (hypersound).
Type:
Grant
Filed:
August 9, 2019
Date of Patent:
July 5, 2022
Assignee:
YALE UNIVERSITY
Inventors:
Eric Kittlaus, Nils Otterstrom, Prashanta Kharel, Shai Gertler, Peter Rakich
Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.
Abstract: Compositions and methods for treating cardiovascular diseases and dyslipidemias are provided. The compositions can inhibit Wnt signaling and can reduce inflammation. The levels of cholesterol can be reduced when the compositions are administered to a subject, such as a human.
Abstract: The invention provides compositions and methods for binding and inhibiting renalase. In one embodiment, the renalase binding molecule inhibits renalase activity. Thus, in diseases and conditions where a reduction of renalase activity is beneficial, such inhibitory renalase binding molecules act as therapeutics.
Type:
Grant
Filed:
April 14, 2020
Date of Patent:
June 28, 2022
Assignee:
Yale University
Inventors:
Gary Desir, Abigail Hunt, Jessica O-Rear, Peter Flynn
Abstract: Core-shell particles and methods of making and using thereof are described herein. The core is formed of or contains one or more hydrophobic materials or more hydrophobic materials. The shell is formed of or contains hyperbranched polyglycerol (HPG). The HPG coating can be modified to adjust the properties of the particles. Unmodified HPG coatings impart stealth properties to the particles which resist non-specific protein absorption and increase circulation in the blood. The hydroxyl groups on the HPG coating can be chemically modified to form functional groups that react with functional groups and adhere the particles to tissue, cells, or extracellular materials, such as proteins.
Type:
Grant
Filed:
March 25, 2019
Date of Patent:
June 21, 2022
Assignee:
YALE UNIVERSITY
Inventors:
Yang Deng, Asiri Ediriwickrema, William M. Saltzman